SCHEDULE: FMR LLC & Abigail Johnson Boost CytomX Stake to 12.4%
Beneficial Ownership Report
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have reported a combined beneficial ownership of 12.4% of CytomX Therapeutics Inc.'s common stock as of October 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson, its Chairman and CEO, collectively reported beneficial ownership of 20,519,967 shares of CytomX Therapeutics Inc. common stock.
- This represents 12.4% of the total outstanding common stock of CytomX Therapeutics Inc.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing.
- FMR LLC, a parent holding company, holds sole voting and dispositive power over these shares.
- Abigail P. Johnson's beneficial ownership is derived from her position and the Johnson family's controlling interest in FMR LLC.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of CytomX Therapeutics Inc.
Sentiment
Score: 7
Explanation: The filing reveals a substantial 12.4% beneficial ownership by FMR LLC and Abigail P. Johnson in CytomX Therapeutics Inc., signaling strong institutional confidence in the company. The declaration that the shares are held in the ordinary course of business and not for control purposes suggests a long-term, passive investment strategy.
Positives
- Increased institutional ownership by a major financial institution like FMR LLC can signal confidence in CytomX Therapeutics Inc.'s long-term prospects.
- A significant stake (12.4%) by a reputable investor may attract further institutional interest.
- The filing explicitly states the shares are held in the ordinary course of business and not for control, suggesting a passive, long-term investment intent.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
This filing indicates a significant, passive investment by a major asset manager (FMR LLC, parent of Fidelity Investments) in a biotechnology company, CytomX Therapeutics Inc. Such an investment suggests FMR LLC sees long-term value in CytomX's pipeline or market position within the competitive biotechnology sector, which is characterized by high R&D costs, regulatory hurdles, and potential for high returns from successful drug development.
Comparison to Industry Standards
- A 12.4% stake by a single institutional investor like FMR LLC is a substantial position, often indicating a high conviction investment. For comparison, many institutional investors hold smaller, diversified stakes across numerous companies.
- FMR LLC's investment strategy, as evidenced by its diverse portfolio, often includes significant positions in growth-oriented sectors like biotechnology. This level of ownership is not uncommon for large asset managers taking a strategic, long-term view in promising companies.
- The explicit statement that the holding is for ordinary course of business and not for control aligns with typical passive institutional investment behavior, differentiating it from activist investor stakes that often aim for board seats or strategic changes.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Beneficial Ownership Structure | FMR LLC and Abigail P. Johnson collectively hold 12.4% of CytomX Therapeutics Inc.'s common stock, with FMR LLC exercising sole voting and dispositive power. Abigail P. Johnson's ownership is attributed through her role and family's control of FMR LLC. | 2025-10-31 | This significant institutional ownership provides a stable shareholder base but does not indicate an intent to influence corporate control, as certified by the reporting persons. |
Stakeholder Impact
- Shareholders: Existing shareholders may view the significant stake by FMR LLC as a positive signal, potentially increasing investor confidence and attracting further investment.
- Management: Management may feel validated by the substantial institutional investment, which could provide stability and support for long-term strategic initiatives.
- Employees: No direct impact on employees is indicated by this ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries, authorizing Stephanie J. Brown to sign. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where its Power of Attorney (Exhibit 24) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson, authorizing Stephanie J. Brown to sign. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Abigail P. Johnson's Power of Attorney (Exhibit 24) was incorporated by reference. |
| 2025-10-31 | Date of event which requires filing of this statement (measurement date for beneficial ownership). |
| 2025-11-06 | Date of signing of this Schedule 13G by Stephanie J. Brown on behalf of FMR LLC and Abigail P. Johnson. |
Recommendation
holdThe filing indicates a significant, passive institutional investment by FMR LLC and Abigail P. Johnson, which is generally a positive signal of confidence in CytomX Therapeutics Inc. However, a Schedule 13G filing primarily discloses ownership and does not provide operational or financial performance updates. Without additional information on the company's fundamentals, pipeline progress, or financial health, a 'hold' recommendation is prudent. The substantial stake suggests long-term potential, but investors should await further company-specific news before making more aggressive investment decisions.
Keywords
CytomX Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.